Answers are grounded in this paper and cite their sources.
Tertiary lymphoid structures (TLSs) arise in non-lymphoid tissues in response to antigenic stimulation combined with inflammation, spanning organs from lung and liver to meninges and skin. These structures exist along a spectrum, from loosely organized immune cell aggregates to highly structured formations containing functional germinal centres. Once regarded primarily as epiphenomena of chronic inflammation and autoimmunity, TLSs are now recognized as dynamic and context-dependent immune niches that can either promote protective immunity or contribute to pathology (Figure 1). This issue of Immunological Reviews brings together a diverse set of perspectives that collectively advance our understanding of TLS biology across evolution, tissue types, and disease contexts. A central theme that emerges is the need to move beyond static definitions toward a more nuanced appreciation of TLS as adaptive, tissue-embedded immune ecosystems. Fundamental insights into TLS biology are framed by revisiting their evolutionary and developmental origins. Salinas and colleagues expand the scope of TLS-like structures to teleost fish, proposing a revised definition of tertiary lymphoid organs that accommodates species lacking classical secondary lymphoid organs. This broader phylogenetic perspective underscores the conserved importance of localized immune organization [1]. Complementing this, Nancy Ruddle highlights how understanding secondary lymphoid organ development and lymphotoxin signaling provides a conceptual and mechanistic foundation for interpreting TLS formation and function [2]. Together, these contributions reinforce the idea that TLSs recapitulate many aspects of canonical lymphoid programs in peripheral tissues. A recurring concept in this issue is the recognition of TLS heterogeneity. Hillion and colleagues introduce a framework distinguishing inflammatory lymphoid structures from mature TLSs, while acknowledging that these may represent points along a continuum rather than discrete entities [3]. Guillaume, Beccaria et al., further integrate this perspective by emphasizing both shared architectural features and tissue-specific adaptations of TLSs, alongside their dual roles in infection, autoimmunity, cancer, and allergy [4]. Extending this theme into barrier tissues, Inta Gribonika explores dermal TLSs as components of intrinsic skin immunocompetence. This review discusses how microbiota-driven, non-inflammatory cues can sustain localized humoral immunity even in healthy tissue [5]. At the cellular level, TLSs emerge as highly collaborative microenvironments shaped by intricate interactions between immune and stromal compartments. Daxing and colleagues dissect the contributions of innate immune cells and receptors to TLS initiation and maintenance [6], while Denton and colleagues highlight the importance of immune–stromal crosstalk across tissues such as kidney, lung, and skin [7]. Rao and colleagues focus on T peripheral helper and T follicular helper-like cells, elucidating their roles in orchestrating B cell responses through key mediators such as CXCL13 and IL-21 [8]. Together, these studies illustrate how coordinated complex cellular networks are critical for TLS formation, organization, and function. The clinical relevance of TLSs is particularly evident in autoimmune diseases, where their roles are and complex. Weyand and colleagues reframe autoimmunity through the lens of aging, proposing that the decentralization of immune responses from central to peripheral sites, via TLS, may underlie both durable immunity in autoimmunity and contribute to inflammaging [9]. In the central nervous system, Gommerman and colleagues discuss leptomeningeal TLSs as hallmarks of progressive multiple sclerosis, linking their presence to more severe pathology and suggesting that targeting TLS organization may offer new therapeutic avenues for central nervous system inflammation [10]. Beyond autoimmunity, TLSs are increasingly recognized as critical determinants of disease outcomes across diverse settings. In cancer, Dieu-Nosjean and colleagues [11], alongside Joshi and colleagues [12], describe a field at an inflection point, where TLSs are associated with improved prognosis and responses to immunotherapy, and where emerging technologies are enabling a transition from descriptive to mechanistic understanding [11]. Joshi and colleagues further describe tractable in vivo models for investigating TLS formation and function in anti-tumor immunity [12]. In infectious disease, King and colleagues examine TLSs in tuberculosis, emphasizing the complex interplay between CD4+ T cells and B cells and the unresolved question of whether TLSs ultimately support or hinder pathogen control [13]. In cardiovascular disease, Habenicht and colleagues introduce artery tertiary lymphoid organs as components of neuroimmune cardiovascular interfaces, revealing an unexpected integration of immune, nervous, and vascular systems that may shape disease progression [14]. Collectively, the contributions in this volume highlight TLSs as versatile and context-dependent structures that bridge innate and adaptive immunity, local and systemic responses, and health and disease. Rather than being mere byproducts of chronic inflammation, TLSs emerge as fundamental organizers of immune function within tissues. Novel approaches to modulate their formation and activity, whether to enhance protective immunity in cancer and infection or to limit pathogenic responses in autoimmunity and inflammaging, represents a central challenge and opportunity for the field to leverage tissue immunity to promote health. As TLS research continues to evolve, integrating insights across disciplines, model systems, pre- and post-treatment, and clinical contexts will be essential. This issue provides a timely synthesis of current knowledge while pointing toward future directions, where targeted manipulation of tissue-based immunity may become an integral component of next-generation therapeutics. M.A.L. is funded by the Malaghan Institute of Medical Research. P.K.M. is an employee of GSK. Figure credit: Figure generated by Claudia Bentley. M.A.L. declares no conflicts of interest. P.K.M. is an employee of GSK. GSK had no additional role in the writing, decision to publish, or preparation of this editorial. Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.
No takes yet. Share an insight, caveat, or question.
Linterman et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: